The European Commission cleared on Friday 10 January the proposed acquisition of Allergan Plc. (Republic of Ireland) by AbbVie Inc. (United States) for $63 billion (56.75 billion euros). Approval is conditional upon the divestment by Allergan of a product for the treatment of inflammatory bowel diseases.
Margrethe Vestager, Executive Vice-President of the Commission, explained that the Commission’s decision ensures that the merger “will not disrupt the development of a promising...